In his weekly clinical update Dr. Griffin discusses variant influenza virus infections: recommendations for identification, treatment, and prevention for summer and fall 2022, low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals, using the right tools at the right time for SARS-COV-2 infection, onset and window of SARS-COV-2 infectiousness and temporal correlation with symptom onset, transmission of SARS-COV-2: a review of viral, host, and environmental factors, antibody persistence and safety through 6 months after heterologous orally aerosolized Ad5-nCoV in individuals primed with two-dose vaccine, timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients, administration of anti–SARS-COV-2 monoclonal antibodies after US Food and Drug Administration deauthorization, and clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• 2022 recommendations for Influenza infections (CDC)
• Low levels of monkeypox neutralizing antibodies after vaccination (medRxiv)
• Using the right tools during SARS-CoV-2 infection (ESMED)
• Onset and window of SARS-CoV-2 infectiousness with symptom onset (The LANCET)
• Transmission of SARS-COV-2 (ACP Journals)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Administration of anti–SARS-COV-2 monoclonal antibodies (JAMA)
• Clinical and genetic risk factors for thromboembolism (JAMA)
• Administration of tocilizumab improves outcomes (PLOS One)
• Antibody persistence and safety through 6 months (medRxiv)
• Improve risk score for thromboembolism (mdCalc)
• Contribute to Floating Doctors fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 934
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]